Subependymal giant cell astrocytoma historical perspective: Difference between revisions
Mahshid |
|||
| Line 21: | Line 21: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | |||
Revision as of 17:00, 27 November 2017
|
Subependymal giant cell astrocytoma Microchapters |
|
Differentiating Subependymal Giant Cell Astrocytoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Subependymal giant cell astrocytoma historical perspective On the Web |
|
American Roentgen Ray Society Images of Subependymal giant cell astrocytoma historical perspective |
|
FDA on Subependymal giant cell astrocytoma historical perspective |
|
CDC on Subependymal giant cell astrocytoma historical perspective |
|
Subependymal giant cell astrocytoma historical perspective in the news |
|
Blogs on Subependymal giant cell astrocytoma historical perspective |
|
Risk calculators and risk factors for Subependymal giant cell astrocytoma historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Russell et al was the first scientist to coin the term "subependymal giant cell astrocytoma".[1]
Historical Perspective
- Russell et al was the first scientist to coin the term "subependymal giant cell astrocytoma".[1]
- Anna et al. was the first to identify that subependymal giant cell astrocytoma demonstrated immunoreactivity for neurofilament, GFAP, substance P, and neuron-specific enolase.
- The transformation of a subependymal nodule into a subependymal giant cell astrocytoma was first described by Nabbout.